Overview : BSI-045A is an anti-IL4Rα humanized antagonist monoclonal antibody with high selectivity and high bioactivity. By binding to interleukin-4 receptor alpha (IL-4Rα), it blocks the action of two proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key mediators of allergic inflammation. BSI-045A was created by Biosion under a collaboration with CTTQ in May 2017. CTTQ owns global rights.
Development status : CTTQ is conducting a Phase 1 clinical study of BSI-045A in atopic dermatitis in China.